辉瑞(PFE.N)停止减肥药Danuglipron的开发，辉瑞表示，参与者出现了潜在的药物引起的肝损伤。

Core Viewpoint - Pfizer (PFE.N) has halted the development of its weight loss drug Danuglipron due to potential drug-induced liver damage observed in participants [1] Company Summary - Pfizer has made the decision to stop the development of Danuglipron, a weight loss medication, after identifying risks associated with liver damage in clinical trial participants [1]